Targeted therapies for pancreatic cancer
Open Access
- 1 August 2008
- journal article
- review article
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 87 (1), 97-130
- https://doi.org/10.1093/bmb/ldn027
Abstract
Pancreatic cancer is a devastating malignancy and a leading cause of cancer mortality. Furthermore, early diagnosis represents a serious hurdle for clinicians, as symptoms are non-specific and usually manifest in advanced, treatment-resistant stages of the disease. Here, we review the rationale and progress of targeted therapies currently under investigation. At present, chemoradiation regimes are administered palliatively, and produce only marginal survival benefits, underscoring a desperate need for more effective treatment modalities. Questions have been raised as to whether erlotinib, the only targeted therapy to attain a statistically significant increase in median survival, is cost-effective. The last decade of research has provided us with a wealth of information regarding the molecular nature of pancreatic cancer, leading to the identification of signalling pathways and their respective components which are critical for the maintenance of the malignant phenotype. These proteins thus represent ideal targets for novel molecular therapies which embody an urgently needed novel treatment strategy.Keywords
This publication has 146 references indexed in Scilit:
- Ras oncogenes and their downstream targetsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- The Effects of mTOR-Akt Interactions on Anti-apoptotic Signaling in Vascular Endothelial CellsOnline Journal of Public Health Informatics, 2007
- Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II studyBritish Journal of Cancer, 2006
- Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancerBritish Journal of Cancer, 2006
- Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trialsBritish Journal of Cancer, 2006
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Inflammation and cancerNature, 2002
- The Hallmarks of CancerCell, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996